-
Novan Inc NASDAQ:NOVN Novan, Inc. is a clinical development-stage biotechnology company focused on leveraging its proprietary nitric oxide (NO) based technology platform, NITRICIL™ to generate macromolecular New Chemical Entities (NCEs) to treat multiple indications in dermatology, men's and women's health, infectious diseases and gastroenterology conditions with significant unmet needs. The Company's lead product candidate, SB206, a topical antiviral gel, for the treatment of molluscum contagiosum, is currently being evaluated in the B-SIMPLE4 pivotal Phase 3 clinical study. The Company believes that SB206 as a topical, at-home, caregiver-applied therapy with a rapid treatment benefit, if approved, would address an important patient-care need for the treatment of molluscum.
Location: 4105 Hopson Rd, North Carolina, 27560-9018, US | Website: www.novan.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
0.00
Cash
126.6M
Avg Qtr Burn
N/A
Short % of Float
1.78%
Insider Ownership
0.45%
Institutional Own.
6.86%
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Berdazimer (SB206) Details Molluscum contagiosum | Approved Quarterly sales | |
SB208 Details Tinea Pedis | Failed Discontinued | |
SB206 Details Human papillomavirus | Failed Discontinued | |
SB204 Details Acne vulgaris | Failed Discontinued | |
SB414 Details Atopic dermatitis | Failed Discontinued |